TXG (10x Genomics) EPS without NRI: $-0.48 (TTM As of Mar. 2026)


TXG 10x Genomics Inc TXG
62 GF Score
Price $38.24
GF Value $18.95
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics EPS without NRI?

10x Genomics TXG -4.40% 62 EPS without NRI is $-0.48 as of Mar. 2026. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.95 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 511 Healthcare Providers & Services companies, 10x Genomics ranks better than 63.01% on this metric.

10x Genomics's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.10. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 6.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for 10x Genomics's EPS without NRI or its related term are showing as below:

TXG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -110.9   Med: -11.75   Max: 23
Current: 23

During the past 9 years, 10x Genomics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 23.00% per year. The lowest was -110.90% per year. And the median was -11.75% per year.

TXG's 3-Year EPS without NRI Growth Rate is ranked better than
63.01% of 511 companies
in the Healthcare Providers & Services industry
Industry Median: 11.5 vs TXG: 23.00

10x Genomics's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.10. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17.

10x Genomics's EPS (Basic) for the three months ended in Mar. 2026 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17.


10x Genomics  (NAS:TXG) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


10x Genomics EPS without NRI Related Terms


10x Genomics EPS without NRI Historical Data

* Premium members only.

The historical data trend for 10x Genomics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics EPS without NRI Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -0.53 -1.46 -1.77 -1.52 -0.67

10x Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.03 -0.22 -0.13 -0.10

TXG vs DOCS, WAY, PRVA: EPS without NRI Comparison

For the Health Information Services subindustry, 10x Genomics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics PE Ratio without NRI vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where 10x Genomics's PE Ratio without NRI falls into.


TXG
62GF Score
10x Genomics Inc TXG
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

10x Genomics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.48 mean?
10x Genomics (TXG) has a EPS without NRI of $-0.48 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #189 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 37%.
Is 10x Genomics' EPS without NRI too high?
10x Genomics' current EPS without NRI is $-0.48. Based on the distribution chart, 10x Genomics ranks #189 out of 511 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' EPS without NRI compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #189 out of 511 companies for EPS without NRI. This puts 10x Genomics in the upper half of its industry. The industry median EPS without NRI is 11.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.50, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current EPS without NRI is $-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.95, compared to a current price of $38.24 — trading 101.8% above its estimated fair value. The current EPS without NRI is $-0.48. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For 10x Genomics (TXG), the current EPS without NRI is $-0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $38.24 is trading 101.8% above its estimated GF Value™ of $18.95. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • EPS without NRI: $-0.48
  • GF Value™: $18.95 vs. price of $38.24 (101.8% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score

Get the complete analysis for TXG

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.24
Price
$18.95
GF Value